Ca/Mg infusions for the prevention of oxaliplatinrelated neurotoxicity in patients with colorectal cancer: A meta-analysis

Annals of Oncology

Volumn 24, Issue 1, 2013, Pages 171-178

  Wen, F ^a   Zhou, Y ^a   Wang, W ^a   Hu, Q C ^a   Liu, Y T ^b   Zhang, P F ^a   Du, Z D ^a   Dai, J ^a   Li, Q ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Calcium; Colorectal cancer; Magnesium; Neurotoxicity; Oxaliplatin

Indexed keywords

CALCIUM; MAGNESIUM; OXALIPLATIN; PLACEBO;

ARTICLE; CANCER SURVIVAL; COLORECTAL CANCER; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERANCE; HUMAN; META ANALYSIS; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUROPROTECTION; NEUROTOXICITY; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EID: 84871567541     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds211     Document Type: Article

References (42)

1. de Gramont A, Figer A, Seymour M et al Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
2. Andre T, Boni C, Mounedji-Boudiaf L et al Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-2351.
3. Andre T, Louvet C, Maindrault-Goebel F et al CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer 1999; 35: 1343-1347.
4. Khattak MA. Calcium and magnesium prophylaxis for oxaliplatin-related neurotoxicity: is it a trade-off between drug efficacy and toxicity? Oncologist 2011; 16: 1780-1783.
5. Giacchetti S, Perpoint B, Zidani R et al Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18: 136-147.
6. Wilson RH, Lehky T, Thomas RR et al Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol 2002; 20: 1767-1774.
7. Cersosimo RJ. Oxaliplatin-associated neuropathy: a review. Ann Pharmacother 2005; 39: 128-135.
8. Armstrong CM, Cota G. Calcium block of Na+ channels and its effect on closing rate. Proc Natl Acad Sci USA 1999; 96: 4154-4157.
9. Gamelin E, Gamelin L, Bossi L et al Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol 2002; 29: 21-33.
10. Grolleau F, Gamelin L, Boisdron-Celle M et al A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol 2001; 85: 2293-2297.
11. Ta LE, Espeset L, Podratz J et al Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicology 2006; 27: 992-1002.
12. Gedlicka C, Scheithauer W, Schull B et al Effective treatment of oxaliplatininduced cumulative polyneuropathy with alpha-lipoic acid. J Clin Oncol 2002; 20: 3359-3361.
13. Jacobsen D, McMartin KE. Methanol and ethylene glycol poisonings. Mechanism of toxicity, clinical course, diagnosis and treatment. Med Toxicol 1986; 1: 309-334.
14. Cannon SC. Ion-channel defects and aberrant excitability in myotonia and periodic paralysis. Trends Neurosci 1996; 19: 3-10.
15. Land SR, Kopec JA, Cecchini RS et al Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol 2007; 25: 2205-2211.
16. Goldberg RM, Sargent DJ, Morton RF et al A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30.
17. Donzelli E, Carfi M, Miloso M et al Neurotoxicity of platinum compounds: comparison of the effects of cisplatin and oxaliplatin on the human neuroblastoma cell line SH-SY5Y. J Neurooncol 2004; 67: 65-73.
18. Mariani G, Garrone O, Granetto C et al Oxaliplatin induced neuropathy: could gabapentin be the answer. Proc Am Soc Clin Oncol 2000; 19.
19. Penz M, Kornek GV, Raderer M et al Subcutaneous administration of amifostine: a promising therapeutic option in patients with oxaliplatin-related peripheral sensitive neuropathy. Ann Oncol 2001; 12: 421-422.
20. Cascinu S, Catalano V, Cordella L et al Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2002; 20: 3478-3483.
21. Lersch C, Schmelz R, Eckel F et al Prevention of oxaliplatin-induced peripheral sensory neuropathy by carbamazepine in patients with advanced colorectal cancer. Clin Colorectal Cancer 2002; 2: 54-58.
22. Wolf S, Barton D, Kottschade L et al Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer 2008; 44: 1507-1515.
23. Gamelin L, Boisdron-Celle M, Delva R et al Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 2004; 10: 4055-4061.
24. Gamelin L, Boisdron-Celle M, Morel A et al Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy. J Clin Oncol 2008; 26: 1188-1189; author reply 1189-1190.
25. Chay WY, Tan SH, Lo YL et al Use of calcium and magnesium infusions in prevention of oxaliplatin induced sensory neuropathy. Asia Pac J Clin Oncol 2010; 6: 270-277.
26. Ishibashi K, Okada N, Miyazaki T et al Effect of calcium and magnesium on neurotoxicity and blood platinum concentrations in patients receiving mFOLFOX6 therapy: a prospective randomized study. Int J Clin Oncol 2010; 15: 82-87.
27. Grothey A, Nikcevich DA, Sloan JA et al Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. J Clin Oncol 2011; 29: 421-427.
28. Knijn N, Tol J, Koopman M et al The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients. Eur J Cancer 2011; 47: 369-374.
29. Chaves J, Patel K, Abdelghany O et al Outcome of intravenous calcium and magnesium (Ca/Mg) in oxaliplatin-containing regimens compared with no Ca/Mg. Journal of Clinical Oncology. 2011 ASCO Annual Meeting Proceedings (Post-Meeting Edition), Chicago: American Society of Clinical Oncology, 2011. Abstract e19681, p. 29.
30. Kemeny N, Garay CA, Gurtler J et al Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer. J Clin Oncol 2004; 22: 4753-4761.
31. Review Manager (RevMan) [Computer program]. Version 5.0. The Nordic Cochrane Centre, The Cochrane Collaboration: Copenhagen, 2008.
32. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0. The Cochrane Collaboration, 2008; http://www.cochrane-handbook.org (7 September 2008, date last accessed).
33. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
34. Demets DL. Methods for combining randomized clinical trials: strengths and limitations. Stat Med 1987; 6: 341-350.
35. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-1558.
36. Egger M, Davey Smith G, Schneider M et al Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
37. Macaskill P, Walter SD, Irwig L. A comparison of methods to detect publication bias in meta-analysis. Stat Med 2001; 20: 641-654.
38. Gluud C, Nikolova D, Klingenberg S et al Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). 2008; Issue 4. Art. No.: LIVER. http://www.mrw.interscience.wiley.com/cochrane/cochrane_clsysrev_crglist_fs.html (6 November 2009, date last accessed).
39. Gurusamy KS, Gluud C, Nikolova D et al Assessment of risk of bias in randomized clinical trials in surgery. Br J Surg 2009; 96: 342-349.
40. de Gramont A, Boni C, Navarro M et al Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: efficacy results with a median follow-up of 4 years. Proc Am Soc Clin Oncol 2005; 23.
41. Wolmark N, Wieland H, Kuebler JP et al A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: results of NSABP Protocol C-07. Proc Am Soc Clin Oncol 2005; 23.
42. Hochster HS, Grothey A, Childs BH. Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity. J Clin Oncol 2007; 25: 4028-4029.